The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Epidemiology of brain metastases and leptomeningeal disease
Open accessAbstract
Brain metastases affect a significant percentage of patients with advanced extracranial malignancies. Yet, the incidence of brain metastases remains poorly described, largely due to limitations of population-based registries, a lack of mandated reporting of brain metastases to federal agencies, and historical difficulties with delineation of metastatic involvement of individual organs using claims data. However, in 2016, the Surveillance Epidemiology and End Results (SEER) program released data relating to the presence vs absence of brain metastases at diagnosis of oncologic disease. In 2020, studies demonstrating the viability of utilizing claims data for identifying the presence of brain metastases, date of diagnosis of intracranial involvement, and initial treatment approach for brain metastases were published, facilitating epidemiologic investigations of brain metastases on a population-based level. Accordingly, in this review, we discuss the incidence, clinical presentation, prognosis, and management patterns of patients with brain metastases. Leptomeningeal disease is also discussed. Considerations regarding individual tumor types that commonly metastasize to the brain are provided.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
A Randomized Trial of Surgery in the Treatment of Single Metastases to the Brain
Patchell, R. A., Tibbs, P. A., Walsh, J. W., Dempsey, R. J., Maruyama, Y., Kryscio, R. J., Markesbery, W. R., Macdonald, J. S., & Young, B. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002223220802 · Cited by 3,135
Gaspar, L., Scott, C., Rotman, M., Asbell, S., Phillips, T., Wasserman, T., McKenna, W. G., & Byhardt, R. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(96)00619-0 · Cited by 2,544
Chang, E. L., Wefel, J. S., Hess, K. R., Allen, P. K., Lang, F. F., Kornguth, D. G., Arbuckle, R. B., Swint, J. M., Shiu, A. S., Maor, M. H., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70263-3 · Cited by 2,475
Andrews, D. W., Scott, C. B., Sperduto, P. W., Flanders, A. E., Gaspar, L. E., Schell, M. C., Werner-Wasik, M., Demas, W., Ryu, J., Bahary, J.-P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16250-8 · Cited by 2,417
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Aoyama, H., Shirato, H., Tago, M., Nakagawa, K., Toyoda, T., Hatano, K., Kenjyo, M., Oya, N., Hirota, S., Shioura, H., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2483 · Cited by 2,213
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116
Kocher, M., Soffietti, R., Abacioglu, U., Villà, S., Fauchon, F., Baumert, B. G., Fariselli, L., Tzuk-Shina, T., Kortmann, R.-D., Carrie, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1655 · Cited by 1,988
Postoperative Radiotherapy in the Treatment of Single Metastases to the Brain: A Randomized Trial
Patchell, R. A., Tibbs, P. A., Regine, W. F., Dempsey, R. J., Mohiuddin, M., Kryscio, R. J., Markesbery, W. R., Foon, K. A., & Young, B. (1998) · JAMA · doi:10.1001/jama.280.17.1485 · Cited by 1,915
Handbook of clinical neurology
(1986) · Journal of Neuroimmunology · doi:10.1016/0165-5728(86)90030-5 · Cited by 1,849
Barnholtz-Sloan, J. S., Sloan, A. E., Davis, F. G., Vigneau, F. D., Lai, P., & Sawaya, R. E. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.149 · Cited by 1,843
Brown, P. D., Jaeckle, K., Ballman, K. V., Farace, E., Cerhan, J. H., Anderson, S. K., Carrero, X. W., Barker, F. G., Deming, R., Burri, S. H., et al. (2016) · JAMA · doi:10.1001/jama.2016.9839 · Cited by 1,671
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,490
Epidemiology of Brain Metastases
Nayak, L., Lee, E. Q., & Wen, P. Y. (2012) · Current Oncology Reports · doi:10.1007/s11912-011-0203-y · Cited by 1,361
Self-citationPlanchard, D., Smit, E. F., Groen, H. J. M., Mazieres, J., Besse, B., Helland, Å., Giannone, V., D'Amelio, A. M., Zhang, P., Mookerjee, B., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30679-4 · Cited by 1,360
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Tawbi, H. A., Forsyth, P. A., Algazi, A., Hamid, O., Hodi, F. S., Moschos, S. J., Khushalani, N. I., Lewis, K., Lao, C. D., Postow, M. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805453 · Cited by 1,321
Brown, P. D., Ballman, K. V., Cerhan, J. H., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30441-2 · Cited by 1,220
Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer
Slotman, B., Faivre-Finn, C., Kramer, G., Rankin, E., Snee, M., Hatton, M., Postmus, P., Collette, L., Musat, E., & Senan, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071780 · Cited by 1,133
Brastianos, P. K., Carter, S. L., Santagata, S., Cahill, D. P., Taylor-Weiner, A., Jones, R. T., Van Allen, E. M., Lawrence, M. S., Horowitz, P. M., Cibulskis, K., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0369 · Cited by 1,082
Goldberg, S. B., Gettinger, S. N., Mahajan, A., Chiang, A. C., Herbst, R. S., Sznol, M., Tsiouris, A. J., Cohen, J., Vortmeyer, A., Jilaveanu, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30053-5 · Cited by 993
Planchard, D., Besse, B., Groen, H. J. M., Souquet, P.-J., Quoix, E., Baik, C. S., Barlesi, F., Kim, T. M., Mazieres, J., Novello, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30146-2 · Cited by 888
Brown, P. D., Gondi, V., Pugh, S., Tome, W. A., Wefel, J. S., Armstrong, T. S., Bovi, J. A., Robinson, C., Konski, A., Khuntia, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02767 · Cited by 846
Cagney, D. N., Martin, A. M., Catalano, P. J., Redig, A. J., Lin, N. U., Lee, E. Q., Wen, P. Y., Dunn, I. F., Bi, W. L., Weiss, S. E., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox077 · Cited by 825
Self-citationDavies, M. A., Saiag, P., Robert, C., Grob, J.-J., Flaherty, K. T., Arance, A., Chiarion-Sileni, V., Thomas, L., Lesimple, T., Mortier, L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30429-1 · Cited by 766
Lin, N. U., Claus, E., Sohl, J., Razzak, A. R., Arnaout, A., & Winer, E. P. (2008) · Cancer · doi:10.1002/cncr.23930 · Cited by 727
Gadgeel, S. M., Gandhi, L., Riely, G. J., Chiappori, A. A., West, H. L., Azada, M. C., Morcos, P. N., Lee, R.-M., Garcia, L., Yu, L., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70362-6 · Cited by 698
Shaw, A. T., Felip, E., Bauer, T. M., Besse, B., Navarro, A., Postel-Vinay, S., Gainor, J. F., Johnson, M., Dietrich, J., James, L. P., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30680-0 · Cited by 659
Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., Queirolo, P., Blank, C. U., Hauschild, A., Beck, J. T., St-Pierre, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70024-x · Cited by 640
Keung, E. Z., & Gershenwald, J. E. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1489246 · Cited by 593
Yang, J. C.-H., Ahn, M.-J., Kim, D.-W., Ramalingam, S. S., Sequist, L. V., Su, W.-C., Kim, S.-W., Kim, J.-H., Planchard, D., Felip, E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3223 · Cited by 571
Confounding by Indication in Clinical Research
Kyriacou, D. N., & Lewis, R. J. (2016) · JAMA · doi:10.1001/jama.2016.16435 · Cited by 565
Takahashi, T., Yamanaka, T., Seto, T., Harada, H., Nokihara, H., Saka, H., Nishio, M., Kaneda, H., Takayama, K., Ishimoto, O., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30230-9 · Cited by 549
Lin, N. U., Borges, V., Anders, C., Murthy, R. K., Paplomata, E., Hamilton, E., Hurvitz, S., Loi, S., Okines, A., Abramson, V., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00775 · Cited by 544
Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., Riely, G. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00614-2 · Cited by 471
Sperduto, P. W., Mesko, S., Li, J., Cagney, D., Aizer, A., Lin, N. U., Nesbit, E., Kruser, T. J., Chan, J., Braunstein, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01255 · Cited by 471
Self-citationResponse Assessment in Neuro-Oncology Clinical Trials
Wen, P. Y., Chang, S. M., Van den Bent, M. J., Vogelbaum, M. A., Macdonald, D. R., & Lee, E. Q. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7511 · Cited by 435
Self-citationRecent trends in epidemiology of brain metastases: an overview.
Tabouret, É., Chinot, O. L., Métellus, P., Tallet, A. R., Viens, P., & Gonçalvès, A. (2012) · PubMed · Cited by 423
Chemotherapy Delivery Issues in Central Nervous System Malignancy: A Reality Check
Muldoon, L. L., Soussain, C., Jahnke, K., Johanson, C., Siegal, T., Smith, Q. R., Hall, W. A., Hynynen, K., Senter, P. D., Peereboom, D. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.9861 · Cited by 417
Yang, J. C. H., Kim, S.-W., Kim, D.-W., Lee, J.-S., Cho, B. C., Ahn, J.-S., Lee, D. H., Kim, T. M., Goldman, J. W., Natale, R. B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00457 · Cited by 395
Brain metastases: epidemiology
(2018) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-811161-1.00002-5 · Cited by 336
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets
Newell, F., Kong, Y., Wilmott, J. S., Johansson, P. A., Ferguson, P. M., Cui, C., Li, Z., Kazakoff, S. H., Burke, H., Dodds, T. J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11107-x · Cited by 334
Leptomeningeal metastases: a RANO proposal for response criteria
Chamberlain, M., Junck, L., Brandsma, D., Soffietti, R., Rudà, R., Raizer, J., Boogerd, W., Taillibert, S., Groves, M. D., Rhun, E. L., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now183 · Cited by 317
Self-citationBrain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study
Martin, A. M., Cagney, D. N., Catalano, P. J., Warren, L. E., Bellon, J. R., Punglia, R. S., Claus, E. B., Lee, E. Q., Wen, P. Y., Haas-Kogan, D. A., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0001 · Cited by 301
Self-citationEpidemiology of Brain Metastases
Sacks, P., & Rahman, M. (2020) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2020.06.001 · Cited by 279
Rapp, S. R., Case, L. D., Peiffer, A., Naughton, M. M., Chan, M. D., Stieber, V. W., Moore, D. F., Falchuk, S. C., Piephoff, J. V., Edenfield, W. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.4508 · Cited by 270
Kaufmann, T. J., Smits, M., Boxerman, J., Huang, R., Barboriak, D. P., Weller, M., Chung, C., Tsien, C., Brown, P. D., Shankar, L., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa030 · Cited by 267
Self-citationLeptomeningeal metastasis from systemic cancer: Review and update on management
Wang, N., Bertalan, M. S., & Brastianos, P. K. (2018) · Cancer · doi:10.1002/cncr.30911 · Cited by 262
Brain metastases: neuroimaging
(2018) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-811161-1.00007-4 · Cited by 223
Rusthoven, C. G., Yamamoto, M., Bernhardt, D., Smith, D. E., Gao, D., Serizawa, T., Yomo, S., Aiyama, H., Higuchi, Y., Shuto, T., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.1271 · Cited by 223
Self-citationPestalozzi, B. C., Holmes, E., de Azambuja, E., Metzger-Filho, O., Hogge, L., Scullion, M., Láng, I., Wardley, A., Lichinitser, M., Sanchez, R. I. L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70017-2 · Cited by 210
Lee, S. J., Lee, J.-I., Nam, D.-H., Ahn, Y. C., Han, J. H., Sun, J.-M., Ahn, J. S., Park, K., & Ahn, M.-J. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182773f21 · Cited by 194
Remon, J., Le Rhun, E., & Besse, B. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.006 · Cited by 194
Park, J. H., Kim, Y. J., Lee, J.-O., Lee, K.-W., Kim, J. H., Bang, S.-M., Chung, J.-H., Kim, J. S., & Lee, J. S. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2011.11.022 · Cited by 174
Leptomeningeal carcinomatosis in patients with breast cancer
Franzoi, M. A., & Hortobagyi, G. N. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.01.020 · Cited by 149
Treatment of NRAS-mutant melanoma
Johnson, D. B., & Puzanov, I. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0330-z · Cited by 139
Subtype switching in breast cancer brain metastases: a multicenter analysis
Hulsbergen, A. F. C., Claes, A., Kavouridis, V. K., Ansaripour, A., Nogarede, C. O., Hughes, M. E., Smith, T. R., Brastianos, P. K., Verhoeff, J. J. C., Lin, N., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa013 · Cited by 120
Brain metastasis: clinical manifestations, symptom management, and palliative care
Noh, T., & Walbert, T. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-12-811161-1.00006-2 · Cited by 101
Frequency and outcomes of brain metastases in patients with HER2‐mutant lung cancers
Offin, M. D., Feldman, D., Ni, A., Myers, M. L., Lai, W. V., Pentsova, E. I., Boire, A. A., Daras, M., Jordan, E., Solit, D. B., et al. (2019) · Cancer · doi:10.1002/cncr.32461 · Cited by 100
Atypical BRAF and NRAS Mutations in Mucosal Melanoma
Dumaz, N., Jouenne, F., Delyon, J., Mourah, S., Bensussan, A., & Lebbé, C. (2019) · Cancers · doi:10.3390/cancers11081133 · Cited by 96
Bander, E. D., Yuan, M., Carnevale, J. A., Reiner, A. S., Panageas, K. S., Postow, M. A., Tabar, V. S., & Moss, N. S. (2021) · Cancer · doi:10.1002/cncr.33459 · Cited by 88
Sperduto, P. W., Mesko, S. M., Li, J., Cagney, D. N., Aizer, A. A., Lin, N., Nesbit, E. G., Kruser, T. J., Chan, J. W. S., Braunstein, S. E., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa025 · Cited by 86
Self-citationMEK targeting in N-RAS mutated metastatic melanoma
Thumar, J. R., Shahbazian, D., Aziz, S. A., Jilaveanu, L. B., & Kluger, H. M. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-45 · Cited by 84
Systemic therapy for metastatic HER2-positive breast cancer
Bredin, P., Walshe, J. M., & Denduluri, N. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.07.008 · Cited by 77
Iorgulescu, J. B., Harary, M., Zogg, C. K., Ligon, K. L., Reardon, D. A., Hodi, F. S., Aizer, A. A., & Smith, T. R. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0067 · Cited by 75
Self-citationKotecha, R. R., Miller, J. A., Venur, V. A., Mohammadi, A. M., Chao, S. T., Suh, J. H., Barnett, G. H., Murphy, E. S., Funchain, P., Yu, J. S., et al. (2017) · Journal of neurosurgery · doi:10.3171/2017.1.jns162797 · Cited by 73
Leptomeningeal metastases from small cell lung carcinoma
Seute, T., Leffers, P., ten Velde, G. P. M., & Twijnstra, A. (2005) · Cancer · doi:10.1002/cncr.21322 · Cited by 68
Systemic therapy for brain metastases
Rick, J. W., Shahin, M. N., Chandra, A., Ore, C. L. D., Yue, J. K., Nguyen, A. T., Yagnik, G., Sagar, S., Arfaie, S., & Aghi, M. K. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.07.012 · Cited by 68
Khan, M. K., & Almasan, A. (2011) · OncoTargets and Therapy · doi:10.2147/ott.s20257 · Cited by 66
Utility of administrative claims data for the study of brain metastases: a validation study
Eichler, A. F., & Lamont, E. B. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9943-z · Cited by 66
Population-based estimates of survival among elderly patients with brain metastases
Lamba, N., Kearney, R. B., Catalano, P. J., Hassett, M. J., Wen, P. Y., Haas-Kogan, D. A., & Aizer, A. A. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa233 · Cited by 52
Self-citationKIT in Melanoma: Many Shades of Gray
Slipicevic, A., & Herlyn, M. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.417 · Cited by 48
Lamba, N., Mehanna, E. K., Kearney, R. B., Catalano, P. J., Haas-Kogan, D. A., Alexander, B. M., Cagney, D. N., Lee, K. A., & Aizer, A. A. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa054 · Cited by 48
Self-citationResponse of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib
Batalini, F., Moulder, S., Winer, E. P., Rugo, H. S., Lin, N., & Wulf, G. M. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00403 · Cited by 46
Guo, R., Schreyer, M., Chang, J. C., Rothenberg, S. M., Henry, D., Cotzia, P., Kris, M. G., Rekhtman, N., Young, R. J., Hyman, D. M., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00021 · Cited by 45
Jung, J.-M., Kim, S., Joo, J., Shin, K. H., Gwak, H., & Lee, S. (2012) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2012.52.3.193 · Cited by 44
Yomo, S., & Hayashi, M. (2014) · Radiation Oncology · doi:10.1186/1748-717x-9-152 · Cited by 33
Qian, J. M., Martin, A. M., Martin, K. L., Hammoudeh, L., Catalano, P. J., Hodi, F. S., Cagney, D. N., Haas-Kogan, D. A., Schoenfeld, J. D., & Aizer, A. A. (2020) · Cancer · doi:10.1002/cncr.33196 · Cited by 33
Self-citationŽnidarič, T., Gugic, J., Marinko, T., Horvat, A. G., Kosir, M. S. P., Golo, D., Pantar, M. I., & Ratoša, I. (2019) · The Breast Journal · doi:10.1111/tbj.13433 · Cited by 28
EGFR mutant locally advanced non-small cell lung cancer is at increased risk of brain metastasis
Mitra, D., Chen, Y., Li, R., Hermann, G., Atkins, K. M., Kozono, D., Baldini, E. H., Aizer, A. A., Chukwueke, U. N., & Mak, R. H. (2019) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2019.06.008 · Cited by 25
Self-citationKiesel, B., Thomé, C. M., Weiß, T., Jakola, A. S., Darlix, A., Pellerino, A., Furtner, J., Kerschbaumer, J., Freyschlag, C. F., Wick, W., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06897-z · Cited by 18
Cited by
Weller, M., Wen, P. Y., Chang, S. M., Dirven, L., Lim, M., Monje, M., & Reifenberger, G. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00516-y · Cited by 592
Self-citationJalalifar, S. A., Soliman, H., Sahgal, A., & Sadeghi-Naini, A. (2022) · Cancers · doi:10.3390/cancers14205133 · Cited by 15
Metadata
- Authors
- Lamba, N., Wen, P. Y., & Aizer, A. A.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-04-28
- Volume
- 23
- Issue
- 9
- Pages
- 1447-1456
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W3159719186
- Cited by
- 406
- References
- 83
- FWCI
- 31.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.